HTG Molecular Diagnostics, Inc. (HTGM) EPS Estimated At $-0.23

March 21, 2018 - By Graig Alexander

 HTG Molecular Diagnostics, Inc. (HTGM) EPS Estimated At $ 0.23

Analysts expect HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report $-0.23 EPS on March, 22 after the close.They anticipate $0.53 EPS change or 69.74 % from last quarter’s $-0.76 EPS. After having $-0.46 EPS previously, HTG Molecular Diagnostics, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 3.24% or $0.18 during the last trading session, reaching $5.38. About 2.33 million shares traded or 14.50% up from the average. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 34.13% since March 21, 2017 and is uptrending. It has outperformed by 17.43% the S&P500.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Among 3 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics has $12.0 highest and $5.0 lowest target. $5.33’s average target is -0.93% below currents $5.38 stock price. HTG Molecular Diagnostics had 14 analyst reports since August 24, 2015 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, January 24. The firm has “Buy” rating given on Tuesday, September 12 by H.C. Wainwright. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating on Thursday, February 1. H.C. Wainwright has “Buy” rating and $6.0 target. Canaccord Genuity maintained the stock with “Buy” rating in Monday, January 8 report. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 8. The firm earned “Buy” rating on Wednesday, December 27 by H.C. Wainwright. Rodman & Renshaw initiated it with “Buy” rating and $5 target in Monday, August 22 report. The rating was maintained by H.C. Wainwright with “Buy” on Friday, July 28. Canaccord Genuity maintained it with “Buy” rating and $5.0 target in Friday, January 5 report. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) on Wednesday, August 9 with “Buy” rating.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $149.81 million. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

More recent HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news were published by: which released: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” on March 12, 2018. Also published the news titled: “HTG Molecular Diagnostics (HTGM) Announces New Australian Patent” on February 26, 2018.‘s news article titled: “HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q3 2017 Results – Earnings …” with publication date: November 08, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.